On December 1, 2023, Alfasigma S.p. A. notified Innovation Pharmaceuticals Inc. of its termination without cause of the Exclusive License Agreement between the parties dated July 18, 2019, which granted Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS). A description of the License Agreement is set forth in the Current Report on Form 8-K filed by the Company on July 22, 2019 and is incorporated herein by reference. Alfasigma terminated the License Agreement following its decision to discontinue further work under the License Agreement.

On December 4, 2023, the parties entered into a mutual release relating to the License Agreement and the Company waived the 60-day notice period for termination without cause by Alfasigma.